<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03260556</url>
  </required_header>
  <id_info>
    <org_study_id>2016-5706</org_study_id>
    <nct_id>NCT03260556</nct_id>
  </id_info>
  <brief_title>Pirfenidone for Progressive Fibrotic Sarcoidosis</brief_title>
  <acronym>PirFS</acronym>
  <official_title>Pirfenidone for Progressive Fibrotic Sarcoidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study comparing pirfenidone versus placebo for patients with advanced fibrotic sarcoidosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who meet the inclusion and exclusion criteria will be randomized to be treated with
      either placebo or pirfenidone at the current approved dosage for idiopathic pulmonary
      fibrosis at a 2:1 pirfenidone to placebo ratio. Patients treated with pirfenidone will be
      titrated using the following schedule:

      One 267 mg capsules three times a day for two weeks. Two 267 mg capsules three times a day
      for two weeks Three 267 mg capsules three times a day thereafter Patients will be instructed
      to take all doses of medication with food. Dosage will be titrated on an individual basis
      depending on patient tolerance of medication.

      Those randomized to placebo will receive the same schedule using placebo tablets.

      Block randomization will be done at each site. Liver function tests will be evaluated as
      listed above. If the patient has an abnormal liver function test, then the dose will be
      adjusted per the company's protocol for commercial drug.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2017</start_date>
  <completion_date type="Anticipated">March 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blind placebo controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time until clinical worsening (TCW)</measure>
    <time_frame>two years</time_frame>
    <description>TCW</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in forced vital capacity (FVC)</measure>
    <time_frame>two years</time_frame>
    <description>Change in forced vital capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CPI</measure>
    <time_frame>two years</time_frame>
    <description>Change in composite physiologic index</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sarcoidosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Pirfenidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pirfenidone titrated to three 267 mg tablets three times a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo titrated to three tablets three times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>Increasing doses</description>
    <arm_group_label>Pirfenidone</arm_group_label>
    <other_name>esbriet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Increasing doses</description>
    <arm_group_label>Placebos</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of sarcoidosis

          -  Pulmonary function testing with a Composite Physiologic Index (CPI) score of greater
             than 40

          -  Patient must have evidence of &gt;20% fibrosis on high resolution cat scan

          -  Patients must be on a stable prednisone therapy for sarcoidosis for at least two
             months and no change in other immunosuppressives in the two months prior to entry into
             study

          -  Age greater than 18 and less than 90.

          -  Able to provide written informed consent for participation in the study

        Exclusion Criteria:

          -  Patients receiving therapy for precapillary pulmonary hypertension.

          -  Patients with liver disease Childs class 3 or 4

          -  Patients with a left ventricular ejection fraction of less than 40%

          -  Patients receiving more than 20 mg prednisone daily or its equivalent

          -  Patients with massive hemoptysis within prior three months. Patients with mycetomas
             are eligible as long as no massive hemoptysis in prior three months.

          -  Patients with clinically important co-existing disease which in the opinion of the
             investigator is likely to affect patient's chance for survival during the course of
             the study

          -  Patient who is pregnant, lactating, intending to become pregnant during the study, or
             child bearing capacity who is not willing to use appropriate birth control methods
             approved by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert P Baughman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert P Baughman, MD</last_name>
    <phone>513-584-5225</phone>
    <email>baughmrp@ucmail.uc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecca Reeves</last_name>
    <phone>513-584-5226</phone>
    <email>Rebecca.Klein@UCHealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert P Baughman, MD</last_name>
      <phone>513-584-5225</phone>
      <email>bob.baughman@uc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elyse E Lower</last_name>
      <phone>513-584-3829</phone>
      <email>ELower@ucmail.uc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2017</study_first_submitted>
  <study_first_submitted_qc>August 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Robert P Baughman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>pulmonary fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Sarcoidosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>no plans yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

